Strategies for Zika drug discovery

Jing Zou, Pei-Yong Shi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalCurrent Opinion in Virology
Volume35
DOIs
StatePublished - Apr 1 2019

Fingerprint

Drug Discovery
Vaccines
Antiviral Agents
Viral Proteins
Pharmaceutical Preparations
Pregnant Women
Fetus
Zika Virus
Clinical Trials

ASJC Scopus subject areas

  • Virology

Cite this

Strategies for Zika drug discovery. / Zou, Jing; Shi, Pei-Yong.

In: Current Opinion in Virology, Vol. 35, 01.04.2019, p. 19-26.

Research output: Contribution to journalReview article

@article{51dff10c48424c61a336b4e5c717214e,
title = "Strategies for Zika drug discovery",
abstract = "Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barr{\'e} syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.",
author = "Jing Zou and Pei-Yong Shi",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.coviro.2019.01.005",
language = "English (US)",
volume = "35",
pages = "19--26",
journal = "Current Opinion in Virology",
issn = "1879-6257",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Strategies for Zika drug discovery

AU - Zou, Jing

AU - Shi, Pei-Yong

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.

AB - Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.

UR - http://www.scopus.com/inward/record.url?scp=85062466219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062466219&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2019.01.005

DO - 10.1016/j.coviro.2019.01.005

M3 - Review article

C2 - 30852345

AN - SCOPUS:85062466219

VL - 35

SP - 19

EP - 26

JO - Current Opinion in Virology

JF - Current Opinion in Virology

SN - 1879-6257

ER -